NAVB vs. IDXX, LNTH, QDEL, NEOG, CLDX, NTLA, MYGN, ACHV, TKNO, and VNRX
Should you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include IDEXX Laboratories (IDXX), Lantheus (LNTH), QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), and VolitionRx (VNRX). These companies are all part of the "diagnostic substances" industry.
IDEXX Laboratories (NASDAQ:IDXX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 2.1% of IDEXX Laboratories shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, IDEXX Laboratories had 7 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 8 mentions for IDEXX Laboratories and 1 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 1.26 beat IDEXX Laboratories' score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the media.
IDEXX Laboratories has higher revenue and earnings than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
IDEXX Laboratories currently has a consensus price target of $580.38, suggesting a potential upside of 16.79%.
IDEXX Laboratories has a net margin of 23.26% compared to IDEXX Laboratories' net margin of 0.00%. Navidea Biopharmaceuticals' return on equity of 63.66% beat IDEXX Laboratories' return on equity.
IDEXX Laboratories has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.
IDEXX Laboratories received 527 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 72.69% of users gave IDEXX Laboratories an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote.
Summary
IDEXX Laboratories beats Navidea Biopharmaceuticals on 13 of the 14 factors compared between the two stocks.
Get Navidea Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Navidea Biopharmaceuticals Competitors List
Related Companies and Tools
